<DOC>
	<DOCNO>NCT00273533</DOCNO>
	<brief_summary>The present study design evaluate hypothesis Angiotensin‚ÄêConverting Enzyme ( ACE ) inhibitor Ramipril improve vascular function reduce marker low-grade chronic inflammation oxidative stress patient Rheumatoid Arthritis .</brief_summary>
	<brief_title>Ramipril Rheumatoid Arthritis</brief_title>
	<detailed_description>The effect 8-week treatment either ramipril placebo study use randomize , double-blind , crossover protocol . After give write informed consent , baseline characteristic include physical examination , ECG , blood sample noninvasive assessment endothelial function obtain . The patient randomly assign receive either ramipril 10mg ( up-titration-scheme : start 2.5mg Week1 , 5mg Week2 follow 2-5mg final 6 week ) follow placebo vice versa.The individual disease-modifying antirheumatic drug therapy continue throughout study . The examination repeat 8 week treatment first 8 week second study drug . At week 1 2 treatment period safety visit schedule .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<criteria>patient rheumatoid arthritis ( 4 7 ARA criterion must fulfil establish diagnosis ) stable background therapy last three month endothelial dysfunction ( FMD &lt; 4 % , FMD : FlowMediatedDilatation ) nonsmoker previous myocardial infarction , coronary intervention coronary surgery previous treatment statin last 6 month previous treatment ACEinhibitors last 6 month uncontrolled hypertension SAP/DAP &gt; 160/90 mmHg ( SAP : Systolic Arterial Pressure , DAP : Diastolic Arterial Pressure ) dyslipidemia ( LDLcholesterol &gt; 4.9 mmol ) normal CRP &lt; 3 mg/l overweight BMI &gt; 35kg/m2 anaemia ( hemoglobin &lt; 10g/dl ) kidney disease ( creatinine &gt; 150 umol/l ) insulindependent diabetes mellitus congestive heart failure ( &gt; NYHA I ) AVBlock &gt; I pregnancy angioedema malignancy chronic infection drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2006</verification_date>
</DOC>